We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




HPV Test with Cytology Adds Little Diagnostic Value

By LabMedica International staff writers
Posted on 03 Jan 2018
The main goal of cervical screening programs is to detect and treat precancer before cancer develops. More...
Human papillomavirus (HPV) testing is more sensitive than cytology for detecting precancer.

Current guidance largely supports inclusion of HPV testing, which is the more sensitive of the two tests for screening for precancers. Guidance documents have varied in their advice on cervical cancer screening, and not all recommend co-testing.

A team of scientists working with US National Cancer Institute (Rockville, MD, USA) quantified the detection of cervical precancer and cancer by co-testing compared with HPV testing alone at Kaiser Permanente Northern California (KPNC, Oakland, CA, USA), where 1,208,710 women age 30 years and older have undergone triennial cervical co-testing since 2003.They analyzed screening histories of 623 preceding cervical cancers and 5,369 precancers.

The team reported HPV testing identified more women subsequently diagnosed with cancer and precancer than cytology. HPV testing was statistically significantly more likely to be positive for cancer at any time point, except within 12 months. HPV-negative/cytology-positive results preceded only small fractions of cases of precancer (3.5%) and cancer (5.9%). These cancers were more likely to be regional or distant stage with squamous histopathology than other cases.

Given the rarity of cancers among screened women, the contribution of cytology to screening translated to earlier detection of at most five cases per million women per year. Two-thirds (67.9%) of women found to have cancer during 10 years of follow-up at KPNC were detected by the first co-test performed. The added sensitivity of co-testing versus HPV alone for detection of treatable cancer affected extremely few women.

Mark Schiffman, MD, MPH, senior investigator at the National Cancer Institute and the study’s lead author, said, “The molecular test detects the virus before the clone of cells is large enough to be readily detectable as abnormal cytology on an exfoliated cell sampling. In other words, first the HPV test turns positive, and then the cytology test is positive if the infected cells reach a size of lesion large enough to be detected when the cervix is scraped for the Pap test.” The study was published on November 14, 2017, in the Journal of the National Cancer Institute.

Related Links:
US National Cancer Institute
Kaiser Permanente Northern California


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers developed three mathematical biomarkers from routine PSA blood tests that may help predict early prostate cancer treatment outcomes and personalize adaptive therapy (Image Credit: Adobe Stock)

Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy

Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read more

Molecular Diagnostics

view channel
Image: The duet mosaic family comprises duet +modC mosaic and duet 6-base mosaic, two cfDNA-optimized multiomic sequencing workflows for liquid biopsy and translational research. (Photo courtesy of bimodal)

New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples

Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.